Charles K. Dargan - 21 Mar 2023 Form 4 Insider Report for BIOLARGO, INC. (BLGO)

Role
Chief Financial Officer
Signature
/s/ John R. Browning, attorney-in-fact
Issuer symbol
BLGO
Transactions as of
21 Mar 2023
Net transactions value
$0
Form type
4
Filing time
27 Mar 2023, 18:32:52 UTC
Previous filing
03 Jan 2023
Next filing
19 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLGO Option to purchase common stock Award +300,000 +7.4% 4,331,500 21 Mar 2023 Common stock 300,000 $0.2000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 21, 2023, and then (ii) in equal monthly installments of 25,000 shares beginning March 31, 2023, so long as the Engagement Extension Agreement dated March 21, 2023, between Reporting Person and Issuer, remains in force and effect.
F2 This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2023, through January 31, 2024.

Remarks:

Reporting person was notified on March 27, 2023 of the issuer's approval of the March 21, 2023 extension agreement.